BrUOG-E-215-neoadjuvant paclitaxel poliglumex (PPX; CT-2103), cisplatin and radiation for esophageal cancer: a phase II trial (CTIX64001)

Trial Profile

BrUOG-E-215-neoadjuvant paclitaxel poliglumex (PPX; CT-2103), cisplatin and radiation for esophageal cancer: a phase II trial (CTIX64001)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2013

At a glance

  • Drugs Cisplatin; Paclitaxel poliglumex
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Feb 2011 Results published in the American Journal of Clinical Oncology, according to a Cell Therapeutics media release.
    • 26 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 24 May 2010 Results will be presented at the American Society of Clinical Oncology 2010 Annual Meeting, according to a Cell Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top